Formulations, methods and procedures for reducing or preventing the development, or the risk of development, of neuropathology as a result of trauma

A formulation adapted for the prevention of the development of neuropathology, or for the amelioration of the effects caused by trauma to a subject, the formulation comprising four biologically active compounds in amounts that are pharmaceutically effective for each compound, respectively, when administered in combination with the other three biologically active compounds, the four compounds comprising a pharmaceutically effective amount of:

• A. at least one biologically active compound from the group comprising anticonvulsants, wherein the anticonvulsant is at least one form of gabapentin;
• B. at least one biologically active compound from the group comprising neurosteroids, wherein the neurosteroid is at least one form of progesterone;
• C. at least one biologically active compound from the group comprising NK-1 receptor antagonists, wherein the NK-1 receptor antagonist is at least one form of aprepitant;
• and
• D. at least one biologically active compound from the group comprising lithium-containing compounds, wherein the lithium-containing compound is at least one form of lithium carbonate;
• wherein the formulation is in a form and a dosage with respect to each of its components such that it is adapted and arranged for administration to a mammal in need thereof, such that the development, or the risk of development, of neuropathology is reduced, lessened, attenuated or prevented.